Previously, cell-cycle pathway dysregulation had been one of the main molecular pathogeneses in ALL, and the use of the CDK4/6 inhibitor played an important role against T-ALL [4,5,6,7]. Here, CDK4 is linked to acute lymphoblastic leukemia.